Evidence map›Paper›PMID 40819168›Full record

Trial reportNature communications2025

Randomized phase I trial outcomes show safe and sustainable inhibition of classical and lectin complement pathways by empasiprubart.

Inge Van de Walle, Laura Bracke, Heidi Gytz Olesen, Tonke van Bragt, Stéphanie Cadour, Phillip De Decker, Giorgia Ciurlia, Erwin Pannecoucke, Emma K Persson, Olivier Van de Steen and 4 more

Abstract readRandomized Controlled TrialClinical Trial, Phase I
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Nature communications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Inge Van de Walle *argenx, Ghent, Belgium. IVandeWalle@argenx.com.ORCID http://orcid.org/0000-0002-7631-399X
Laura Bracke *argenx, Ghent, Belgium.ORCID http://orcid.org/0009-0002-0221-9359
Heidi Gytz OlesenDepartment of Molecular Biology and Genetics - Protein Science, Universitetsbyen 81, 8000, Aarhus C, Denmark.
Tonke van BragtCurare Consulting BV, Liempde, The Netherlands.
Stéphanie Cadourargenx, Ghent, Belgium.
Phillip De Deckerargenx, Ghent, Belgium.
Giorgia Ciurliaargenx, Ghent, Belgium.
Erwin Pannecouckeargenx, Ghent, Belgium.ORCID http://orcid.org/0000-0003-3014-1851
Emma K Perssonargenx, Ghent, Belgium.
Olivier Van de Steenargenx, Ghent, Belgium.
Xinghong Lengargenx, Ghent, Belgium.
Gregers Rom AndersenDepartment of Molecular Biology and Genetics - Protein Science, Universitetsbyen 81, 8000, Aarhus C, Denmark.ORCID http://orcid.org/0000-0001-6292-3319
Domenica Gandini *argenx, Ghent, Belgium.
C Erik Hack *argenx, Ghent, Belgium.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Activation of classical and lectin complement pathways contributes to several human diseases. Empasiprubart is a humanized recycling monoclonal antibody that inhibits both pathways by binding to the CCP2 domain of complement factor 2 (C2), an interaction that is dependent on both Ca

Indexed as

Antibodies, Monoclonal, HumanizedComplement Pathway, ClassicalComplement Pathway, Mannose-Binding LectinAdultDouble-Blind MethodFemaleHealthy VolunteersHumansLectinsMaleMiddle AgedYoung AdultAntibodies, Monoclonal, HumanizedLectins

Identifiers

PMID40819168
PMCPMC12357863

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.